Dr. Zarnegar is a member of the Division of Experimental Pathology.
Dr. Zarnegar's lab is committed to rigorous, innovative, and impactful science and to publishing our discoveries in leading scientific journals. We encourage trainees to think boldly, pursue important questions, and strive for the highest standards of scientific excellence.
The Zarnegar laboratory investigates the molecular mechanisms that maintain liver metabolic homeostasis and how disruption of these pathways contributes to metabolic liver disease, inflammation, fibrosis, and hepatocellular carcinoma. A major focus of our research is understanding how growth factor and metabolic signaling pathways—including the hepatocyte growth factor (HGF)–MET pathway and insulin- and nutrient-responsive signaling networks—communicate to coordinate hepatocyte metabolism, survival, regeneration, and tissue repair. We are particularly interested in how alterations in these signaling networks drive the transition from metabolic dysfunction and steatohepatitis, cirrhosis to advanced end stage liver disease and cancer.
His laboratory combines molecular and cellular biology, biochemistry, genetically engineered animal models, human tissues, primary human hepatocytes, and transcriptomic and single-cell approaches to uncover mechanisms of liver disease and identify new therapeutic opportunities. Current projects span fundamental signal-transduction and metabolism questions as well as translational studies aimed at restoring hepatocyte function and regenerative signaling in metabolic and inflammatory liver diseases. Graduate students in the laboratory have opportunities to integrate mechanistic discovery with clinically relevant models and human data, with the goal of translating fundamental insights in liver biology into new approaches for preventing and treating chronic liver disease and liver cancer.
Laboratory Members
Lab Manager: Dr. Xinping Tan
Current Lab Members: Dr. Jihong Ma, Research Assistant Professor, Dr. Yong Kook Kwon, Research Associate
NIH Research
View Dr. Zarnegar's NIH RePORT on nih.gov
View Dr. Zarnegar's publications on PubMed
- Seneviratne, D, Ma, J, Tan, X, Kwon, YK, Muhammad, E, Melhem, M, DeFrances, MC, Zarnegar, R, Genomic Instability Causes HGF Gene Activation in Colon Cancer Cells, Promoting Their Resistance to Necroptosis. Gastroenterology 2015: 148: 181-91 PMID: 25244939
- Ma, J, Zou, C, Guo, L, Seneviratne, DS, Tan, X, Kwon, YK, An, J, Bowser, R, DeFrances, MC, Zarnegar, R, A novel Death Defying Domain in Met entraps the active site of Caspase-3 and blocks apoptosis in hepatocytes. Hepatology 2014: 5: 2010-14 PMID: 24122846
- Fafalios A, Ma J, Tan X, Stoops J, Luo J, DeFrances MC, Zarnegar R, A hepatocyte growth factor receptor (Met)-insulin receptor hybrid governs hepatic glucose metabolism. Nature Medicine 2011: 17: 1577-84. PMID: 22081023
- Ma J, DeFrances MC, Zou C, Johnson C, Ferrell R, Zarnegar R, Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer. J Clin Invest 2009;119: 478-91. PMID: 19188684
- Zou C, Ma J, Wang X, Guo L, Zhu Z, Stoops J, Eaker AE, Johnson CJ, Strom S, Michalopoulos GK, DeFrances MC, Zarnegar R, Lack of Fas antagonism by Met in human fatty liver disease. Nat Med 2007;13: 1078-85. PMID: 17704785
- Wang X, DeFrances MC, Dai Y, Pediaditakis P, Johnson C, Bell A, Michalopoulos GK, Zarnegar R, A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell 2002;9: 411-21. PMID: 11864613
